

1614

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/016,327	
	Filing Date	December 13, 2001	
	First Named Inventor	Kirvan, Howard C.	
	Art Unit	1614	
	Examiner Name		
Total Number of Pages in This Submission	37	Attorney Docket Number	44921-10203

RECEIVED
APR 09 2003
TECH CENTER 1600/2900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Request for Withdrawal as Attorney or Agent with accompanying documents	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Vorys, Sater, Seymour and Pease, LLP Thomas R. Boland
Signature	
Date	April 4, 2003


CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____			
Typed or printed			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select 2.

APPROVED
JOHN E. KITTLE
DIRECTOR
TECHNOLOGY CENTER 3700 & 2800

12/1/2003



REQUEST FOR WITHDRAWAL AS ATTORNEY OR AGENT

Application Number	10/016,327
Filing Date	December 13, 2001
First Named Inventor	Howard C. Krivan
Art Unit	1614
Examiner Name	
Attorney Docket Number	44921- 10203

RECEIVED
APR 09 2003
TECH CENTER 1600/2900

To: Commissioner for Patents
Washington, DC 20231

I hereby apply to withdraw as attorney or agent for the above identified patent application.


The reasons for this request are:

Failure of client to respond to repeated requests for instructions & for requests to transfer files to new counsel

- ☐ The correspondence address is NOT affected by this withdrawal.
- ☒ Change the correspondence address and direct all future correspondence to:

CORRESPONDENCE ADDRESS

☐ Customer Number



Place Customer Number
Bar Code Label Here

OR

<input checked="" type="checkbox"/> Firm or Individual Name	Mr. Bruce Rose				
Address	Legere Pharmaceuticals, Ltd.				
Address	3123 Research Way, Suite 215				
City	Carson City	State	NV	Zip	89706
Country	USA				
Telephone	702-841-1981			Fax	702-841-2263

- ☒ This request is made on behalf of myself and
- ☒ all the attorneys/agents of record.
 - ☐ the attorneys/agents (with registration numbers) listed on the attached paper(s), or
 - ☐ the attorneys/agents associated with Customer Number

This request is enclosed in triplicate (including any attachments).

Name Thomas R. Boland (Reg. 24093)

Signature

Date April 4, 2003

NOTE: Withdrawal is effective when approved rather than when received. Unless there are at least 30 days between approval of withdrawal and the expiration date of a time period for response or possible extension period, the request to withdraw is normally disapproved.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO, to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Vorys, Sater, Seymour and Pease LLP

1828 L Street NW • Eleventh Floor • Washington, D.C. 20036-5109 • Telephone (202) 467-8800 • Facsimile (202) 467-8900

RECEIVED
APR 09 2003
TECH CENTER 1600/2900

Andrew J. Vorys
1875-1033
Lowry B. Sater
1875-1035
Augustine J. Seymour
1875-1028
Edw. L. Pease
1875-1024

in Columbus
52 East Cleveland Street
Post Office Box 1008
Columbus, Ohio 43260-0008
Telephone (614) 462-6100
Facsimile (614) 462-6150
Cable address

in Cleveland
2100 One Cleveland Center
1475 East Ninth Street
Cleveland, Ohio 44114-1721
Telephone (216) 376-0100
Facsimile (216) 376-0099

in Chicago
Suite 2000 C, Arapp Tower
221 East Fourth Street
Post Office Box 9236
Chicago, Illinois 60604-0236
Telephone (312) 723-4000
Facsimile (312) 723-4050

in Alexandria
277 South Washington Street
Suite 410
Alexandria, Virginia 22314
Telephone (703) 837-6990
Facsimile (703) 549-4492

Thomas R. Boland
Direct Dial (202) 467-8802
Facsimile (202) 533-9017
E-Mail: trboland@vssp.com

March 7, 2003

VIA FACSIMILE

Mr. Bruce Rose
Legere Pharmaceuticals, Ltd.
3123 Research Way, Suite 215
Carson City, NV 89706

Dear Bruce:

As discussed in our recent conversation, and noted in our letter to you of February 11th, we will no longer be in a position to represent Legere in connection with patent prosecution. Therefore, it is imperative that you retain other counsel so that they can take over this responsibility no later than April 15, 2003. In the interim, the following items require your attention:


44921-10107 – Final response due to office action. We have discussed this matter, and Howard was to send his comprehensive information along with payment no later than March 6. So far, we have received nothing on this matter. We have to present the information to the foreign agent no later than **March 10, 2003**. If no response is filed the case will become abandoned.

44921-10008 – Final response due to office action. A response is due no later than **April 2, 2003**.

We have written to you with regard to each of these items, but for your convenience, we are attaching hereto a copy of our letters.

We require your instructions and advance payment in order to deal with these matters. Failing your input, we will take no action to keep these cases alive.

Yours sincerely,


Thomas R. Boland

TRB/dmf

Vorys, Sater, Seymour and Pease LLP

1828 L Street NW • Eleventh Floor • Washington, D.C. 20036-5109 • Telephone (202) 467-8800 • Facsimile (202) 467-8900

Arthur J. Vorys
(877) 601-1111
Lester E. Sater
(867) 911-1111
Virginia T. Seymour
(877) 892-6124
Edward L. Pease
(877) 892-6124

In Columbus
52 East 15th Street
Post Office Box 1008
Columbus, Ohio 43261-0008
Telephone: (614) 464-6300
Facsimile: (614) 464-6356
Cable: vsssp

In Cleveland
2100 One Cleveland Center
1375 East Ninth Street
Cleveland, Ohio 44114-1724
Telephone: (216) 470-6100
Facsimile: (216) 470-6000

In Cincinnati
Suite 2000 • Fifth Floor
221 East Fourth Street
Post Office Box 9246
Cincinnati, Ohio 45201-4236
Telephone: (513) 723-4000
Facsimile: (513) 723-4056

In Alexandria
277 South Washington Street
Suite 310
Alexandria, Virginia 22314
Telephone: (703) 837-6000
Facsimile: (703) 549-4492

Thomas R. Boland
Direct Dial (202) 467-8802
Facsimile (202) 533-9017
E-Mail: trboland@vssp.com

March 3, 2003

VIA FACSIMILE

Howard Krivan, Ph.D.
Legere Pharmaceuticals, Ltd.
3123 Research Way, Suite 215
Carson City, NV 89706

Re: European Patent Application No.: 96 920 576.4
Applicant: Lectin Biopharma, Inc.
Title: METHOD OF USING LECTINS FOR PREVENTION AND
TREATMENT OF SKIN DISEASES AND DISORDERS
Our Ref: 44921-10107

Dear Howard:

In our telephone discussion of March 3, 2003, Bruce raised the issue of the case due next week. The response is due no later than **March 9, 2003** in the above matter.

In order to respond to this action and issue instructions to the foreign agent, I need your detailed analysis from a technical standpoint. Since time is of the essence, I need to have your response no later than **March 6, 2003**.

This is very important if we are to retain your rights in Europe.

Yours sincerely,


Thomas R. Boland

TRB/dmf

Enclosures

Vorys, Sater, Seymour and Pease LLP

1828 L Street NW • Eleventh Floor • Washington, D.C. 20036-5109 • Telephone (202) 467-8800 • Facsimile (202) 467-8900

Arthur J. Vorys
1875 P.O. Box
1875 L Street
1875 P.O. Box
Washington, D.C. 20036
Telephone (202) 467-8800
Facsimile (202) 467-8900

Mr. Columbus
1875 L Street
Post Office Box 1098
Columbus, Ohio 43260-0908
Telephone (614) 461-0100
Facsimile (614) 461-0100
Columbus, Ohio

Mr. Cleveland
1875 L Street
Post Office Box 1098
Cleveland, Ohio 44114-0908
Telephone (216) 471-0100
Facsimile (216) 471-0100
Cleveland, Ohio

Mr. McManis
1875 L Street
Post Office Box 1098
Cleveland, Ohio 44114-0908
Telephone (216) 471-0100
Facsimile (216) 471-0100
Cleveland, Ohio

Mr. McManis
177 South Washington Street
Suite 110
Alexandria, Virginia 22314
Telephone (703) 837-0900
Facsimile (703) 837-0900

07 October 2002

Dr. Howard C. Krivan
President
Legere Pharmaceuticals, Ltd.
3123 Research Way, Suite 215
Carson City, NV 89706

REMINDER 12/19/02
1/3/03

Re: European Patent Application No. 96 920 576 - Method of
Using Lectins for Prevention and Treatment of Skin Diseases
and Disorders - based on PCT Application Publication No.
WO 96/38162 (priority, U.S. Application No. 08/453,281,
30 May 1995)

Our Ref.: 44921-10107 (formerly 00006)

Dear Howard:

The prosecution of the above-identified European patent application has now progressed to the point that the examiner has issued a first examination report. In order to provide you with a convenient collection of relevant documents we include the following items:

- PCT Published Application
- International Search report and references cited therein
- Supplemental European search report and references (including Legere published applications)
- European examination report with copy of claims as amended for European application (marked to show claims examined)

We have not reviewed the examination report in any detail at this time. You will note that the Examiner has not examined Claims 6, 7, and 9 because they relate to separate inventions which were not searched. He also considers Claim 8, related to treating syphilis, as a separate invention, and does not consider it further. Claims that are removed from consideration as lacking unity can be eventually filed in divisional applications. The Examiner also rejects Claims 10 and 11 (cosmetic method and method of treating body odor, respectively) as not patentable subject matter in Europe.

Dr. Howard C. Krivan

- 2 -

44921-10107 EP

As to the examined claims, our European associate remarks that the Examiner seems to acknowledge that the cited prior art does not disclose the treatment of the dermis with a lectin, and therefore objects to the medical use claims as lacking inventive step (i.e., obvious), rather than lacking novelty. Our associate also suggests that it may be possible to overcome the Examiner's rejection of Claims 1 and 2 as lacking novelty by amending the claim to recite a "topical composition". (The subsequent phrase "for administering lectins to the skin" is not considered, in European practice, to distinguish the dermal composition from those administered to the eye, etc.) However, the rejection for lack of inventive step (obviousness) will have to be addressed.

The initial term for filing a response to the examination report is set for

09 January 2003.

A two-month extension of time is possible at a cost of about \$300.00. HOWEVER, NO FURTHER EXTENSIONS OF TIME ARE POSSIBLE. FURTHERMORE, CONTINUATION APPLICATIONS ARE NOT POSSIBLE IN EUROPEAN PRACTICE.

Accordingly, a substantive response to this examination report will have to be filed no later than

09 March 2003.

FAILURE TO FILE A RESPONSE RESULTS IN ABANDONMENT OF THE APPLICATION.


The preparation and filing of a substantive response to the examination report with arguments and any amendments to the claims will evidently require extensive review of the prior art (possibly translation of the Russian language reference) and formulation of appropriate arguments. We will then instruct our European associate, who will prepare and file the response. The costs for preparing and filing such a response will be substantial. After consulting with the European associate about his projected costs, we estimate that the expenses of preparing and filing a response may well amount to \$5000.00.

Accordingly, we will not undertake to review and analyze the references without your instructions and advance payment of the costs. Furthermore, in view of the time required for review of the references and formulation of arguments, sending instructions to the European associate, and his efforts in preparing the response to be filed, at least one month must be

allowed for these activities. Last minute instructions will not allow for preparing an adequate response.

We look forward to your instructions for further prosecution of this European application.

Yours sincerely,


Thomas R. Bolland

enc.: Examination report
Supplemental European Search Report and references
International Search Report and references
Published PCT application

cc: Dr. R.C. Potter w/enc.

TRB/GWS
LEG06L56

Vorys, Sater, Seymour and Pease LLP

1828 L Street NW • Eleventh Floor • Washington, D.C. 20036-5109 • Telephone (202) 467-8800 • Facsimile (202) 467-8900

ARTHUR J. VORYS
1873-0943
LEWIS B. SATER
1847-0945
AUGUSTUS T. SEYMOUR
1873-0926
EDWARD L. PEASE
1873-0924

IN COLUMBIA
520 First Street, NW
Post Office Box 1000
Columbia, MD 21044-1000
Telephone (410) 582-2000
Facsimile (410) 582-1700
Cable 100000

IN CLEVELAND
2100 The Cleveland Center
1375 East Ninth Street
Cleveland, OH 44114-1724
Telephone (216) 579-6100
Facsimile (216) 579-6000

IN CHICAGO
Suite 2000 • Union Tower
221 East Lomb Street
Post Office Box 0236
Chicago, IL 60601-0236
Telephone (312) 723-1000
Facsimile (312) 723-1050

IN ALEXANDRIA
277 South Washington Street
Suite 114
Alexandria, Virginia 22314
Telephone (703) 837-6000
Facsimile (703) 549-4492

Thomas R. Boland
Direct Dial (202) 467-8802
Facsimile (202) 533-9017
E-Mail - trboland@vssp.com

February 21, 2003

VIA FACSIMILE

Dr. Howard Krivan
Legere Pharmaceuticals, Ltd.
3123 Research Way, Suite 215
Carson City, NV 89706

Re: European Patent Appl. No.: 96 905 412.1
Applicant: Legere Pharmaceuticals, Ltd.
Title: METHOD OF USING LECTINS FOR PREVENTION AND
TREATMENT OF ORAL AND ALIMENTARY TRACT
DISORDERS
Our Ref: 44921-10008

Dear Howard:

This is to give you advance notice that the final due date for response to the outstanding Office Action is **April 2, 2003**. Attached is a copy of our letter of November 6, 2002, which sets out the substance of the Office action. In deciding if you want to pursue this matter, please note the anticipated costs on page 3 of our letter.

Also please note our letter of February 11, 2003, regarding the discontinuance of services in connection with patent prosecution. It will be necessary to inform the foreign agent of this fact and identify a new instructing counsel in the US.

It is extremely important that you attend to this matter right away.

Yours sincerely,



Thomas R. Boland

Enclosures

Vorys, Sater, Seymour and Pease LLP

1828 L Street NW • Eleventh Floor • Washington, D.C. 20036-5109 • Telephone (202) 467-8800 • Facsimile (202) 467-8900

Washington, D.C.
1828 L Street NW
Eleventh Floor
Washington, D.C. 20036-5109
Telephone (202) 467-8800
Facsimile (202) 467-8900

New York, N.Y.
1219 Broadway
Fourteenth Floor
New York, N.Y. 10020-3009
Telephone (212) 479-6000
Facsimile (212) 479-6001

Cleveland, Ohio
2100 Lakeside Center
1377 East Ninth Street
Cleveland, Ohio 44114-1071
Telephone (216) 479-6000
Facsimile (216) 479-6001

San Francisco, California
2211 California Street
Fourteenth Floor
San Francisco, California 94109-1071
Telephone (415) 774-6000
Facsimile (415) 774-6001

Alexandria, Virginia
1775 North Washington Street
Suite 100
Alexandria, Virginia 22314
Telephone (703) 836-6000
Facsimile (703) 836-6001

06 November 2002

Dr. Howard C. Krivan
President
Legere Pharmaceuticals, Ltd.
3123 Research Way, Suite 215
Carson City, NV 89706

REMINDER 11/2/02

Re: European Patent Application No. 96 905 412.1 - Method of Using Lectins for Prevention and Treatment of Oral and Alimentary Tract Disorders - based on PCT Application Publication No. WO 96/24368 (priority, U.S. Application No. 08/385,306, 07 February 1995)

Our Ref.: 44921-10008 (formerly 44921-00006)

Dear Howard:

The prosecution of the above-identified European patent application has now progressed to the point that the examiner has issued a first examination report. In order to provide you with a convenient collection of relevant documents we include the following items:

- PCT Published Application
- International Search report and references cited therein
- Supplemental European search report and references)
- European examination report with copy of claims as amended for European application. Note that the claims have been amended and their number has been reduced according to European practice, which permits multiple dependent claims but does not permit claims to methods of treatment practiced on the human body.

We have not reviewed the examination report in any detail at this time. However, we paraphrase below the initial comments made by our European associate attorney on the European examination report.

The Examiner suggests that the claims are lacking in novelty based on three prior publications. Document D1 (European Patent Application No. EP-A-481701, "the '401 application") comes from the International Search Report (incorrectly identified therein, as the examiner points out).

Dr. Howard C. Krivan

- 2 -

44921-10107 EP

Documents D2 (Weinberg et al., Interaction of *Treponema denticola* TD-4, GM-1 and MS25 with human gingival fibroblasts, Infection and Immunity 1990, 58(6), 1720-1729 (June 1990), "the Weinberg reference") and D3 (U.S. Patent 4,742,046, to Bliah, "the '046 patent") are taken from the European Supplementary Search Report.

All of these cited references disclose the binding of lectins to infective agents, either bacteria or viruses. However, the Examiner's assessment of D1 (the '401 application) does not take full note of its actual disclosure. Although it shows the binding of lectins to infective agents, there is no indication that this is itself of therapeutic value. The lectins are used to bind a liposome to infective material, and the antibacterial or antiviral activity is provided by another material carried in the liposome.

Document D2 (the Weinberg reference) is perhaps the most relevant prior art since it shows the binding of lectins to *T. denticola*, which is mentioned in the present application. However, your comments are welcome on whether there is any suggestion that the binding of the lectin suggests an anti-infective therapy.

The Examiner suggests that the prior art disclosures mean that there is nothing inventive left in the present application. However, the biological data present in the application shows activity against the significant microorganism *H. pylori*, and possibly this could be used as the basis of a claim which is both novel and inventive over the cited art.

The Examiner raises some relatively minor matters in paragraphs 4 and 5 of the report. The matters raised in paragraph 5 can be dealt with when your comments are available on the prior art and possible amendments to distinguish from it.

With regard to paragraph 4, "sWGA" has been identified in the description as "suc-WGA" and "Lotus" has been identified as "LTA". As for the suggestion that "PSA" can be confused with another material, we can argue that in a claim that is explicitly referring to lectins, "PSA" will be understood as being the lectin identified in the description.

Dr. Howard C. Krivan

- 3 -

44921-10107 EP

The initial term for filing a response to the examination report is set for

02 February 2003.

A two-month extension of time is possible at a cost of about \$300.00. HOWEVER, NO FURTHER EXTENSIONS OF TIME ARE POSSIBLE. FURTHERMORE, CONTINUATION APPLICATIONS ARE NOT POSSIBLE IN EUROPEAN PRACTICE.

Accordingly, a substantive response to this examination report will have to be filed no later than

02 April 2003.


FAILURE TO FILE A RESPONSE RESULTS IN ABANDONMENT OF THE APPLICATION.

The preparation and filing of a substantive response to the examination report with arguments and any amendments to the claims will evidently require extensive review of the prior art and formulation of appropriate arguments. We will then instruct our European associate, who will prepare and file the response. The costs for preparing and filing such a response will be substantial. We estimate that the expenses of preparing and filing a response may well amount to \$5000.00-\$6000.00.

Accordingly, we will not undertake to review and analyze the references without your instructions and advance payment of the costs. Furthermore, in view of the time required for review of the references and formulation of arguments, sending instructions to the European associate, and his efforts in preparing the response to be filed, at least one month must be allowed for these activities. Last minute instructions will not allow for preparing an adequate response.

We look forward to your instructions for further prosecution of this European application.

Yours sincerely,


Thomas R. Boland

enc.: Examination report
Supplemental European Search Report and references
International Search Report and references
Published PCT application

cc: Dr. R.C. Potter w/enc.

TRB/GWS
LEG03L38

Vorys, Sater, Seymour and Pease LLP

1828 L Street NW • Eleventh Floor • Washington, D.C. 20036-5109 • Telephone (202) 467-8800 • Facsimile (202) 467-8900

Arthur J. Vorys
1873-1923
LLOYD E. SATER
1873-1923
AUGUSTUS T. SEYMOUR
1873-1926
Edward L. Pease
1873-1924

In Columbus
32 Lathrop Street
Post Office Box 10008
Columbus, Ohio 43216-1008
Telephone (614) 264-6400
Facsimile (614) 264-6350
Circle Vorys sign

In Cleveland
2160 One Cleveland Center
1375 East Ninth Street
Cleveland, Ohio 44114-1724
Telephone (216) 479-6100
Facsimile (216) 479-6000

In Cincinnati
Suite 2000 • Arrium Two
221 East Fourth Street
Post Office Box 9236
Cincinnati, Ohio 45201-9236
Telephone (513) 723-4000
Facsimile (513) 723-4050

In Alexandria
277 South Washington Street
Suite 410
Alexandria, Virginia 22314
Telephone (703) 837-6999
Facsimile (703) 549-4492

Thomas R. Boland
Direct Dial (202) 467-8802
Facsimile (202) 533-9017
E-Mail - trboland@vsssp.com

February 11, 2003

CERTIFIED MAIL – RETURN RECEIPT

Mr. Bruce Rose
Howard C. Kirvan, Ph.D.
Leger Pharmaceuticals, Ltd.
3123 Research Way, Suite 215
Carson City, NV 89706

Re: Patent Law Representation

Dear Bruce and Howard:

Our Firm has given considerable thought to how we want to restructure the patent practice which we have been conducting for many years. We have retained consultants to assist us in this deliberation and, in the end, the Firm has decided to discontinue all patent prosecution aspects of our practice. As you probably know, patent prosecution includes searching prior art for patentability, preparing patent applications and dealing with the Patent and Trademark Office or foreign regulatory bodies in the course of obtaining a patent, and maintaining patent applications and issued patents by attending to annuity and maintenance payments.

We will continue our practice of general counseling, providing infringement and validity opinions, and litigation in the Federal Courts. However, we will no longer be involved in that part of the practice described above.

Attached is a list of those applications which we have handled on your behalf. Also enclosed is a list of those cases requiring annuity payments and/or maintenance fees, which we have been processing through Computer Packages Annuity Service, Inc. (CPI).

With regard to the pending applications, it will be necessary for you to retain other counsel by **February 28, 2003**. In each case, a Revocation of Power of Attorney will be necessary, and we have enclosed herewith a document for each individual case. Please sign the document where indicated and return the executed copy to me by return mail or facsimile, so that they may be promptly filed in the United States Patent and Trademark Office or other relevant agencies. At that point, I will send the relevant files to you or to your designee. If you have

February 11, 2003

Page 2

retained other counsel, they may advise you on the type of revocation they would prefer, and in that case they would undoubtedly wish to file the revocation themselves.


With regard to the annuity and maintenance payments, I suggest that you either contact CPI directly or assign the responsibility for payment to your new counsel if that is the case. CPI's address and relevant information is as follows:

Computer Packages Annuity Service, Inc.
414 Hungerford Drive
Rockville, MD 20850
Telephone: 301/424-8890
Facsimile: 301/762-8663

Please note that Legere/Lectin Labs continues to have outstanding debt to the Vorys Sater firm. A ledger sheet is attached to show the extent of that obligation. Please pay this amount in full as soon as possible.

If you wish to discuss the matter further, please let me know.

Yours sincerely,



Thomas R. Boland

TRB/dmf

Enclosures